Testing of the Integrated Rapid Access to HIV Prevention Program for

Status Completed

Clinical Trial Summary

This is a pilot study of an integrated rapid access HIV prevention program for People who inject drugs (PWID) called iRaPID. The program incorporates same-day access to Pre-exposure Prophylaxis (PrEP) and Opioid Agonist Therapy (OAT).

Clinical Trial Description

A Hybrid type 1 implementation science design,will be used to pilot test the APN-led iRaPID program while exploring information on its implementation at multiple time points through the study. The hybrid type 1 pilot trial provides an implementation heuristic to assess potential research questions, perhaps more comprehensively, accurately and certainly earlier than could be achieved in a sequential 'intervention-then-preliminary-pilot study' strategy. In this hybrid type 1 pilot trial, the RCT will be utilized to: - Examine feasibility and acceptability among PWID and clinical stakeholders for an adapted APN-delivered, rapid HIV prevention program for PWID (iRaPID) that integrates same-day PrEP and OAT. - Estimate the preliminary efficacy of PrEP and OAT uptake in a pilot randomized controlled trial of the iRaPID vs. treatment as usual strategy in PWID without HIV. To assess future scale-up factors, the Consolidated Framework for Implementation Research (CFIR) will be utilized with the nominal group technique (NGT). It is a conceptual framework developed to guide the assessment of multilevel implementation contexts. The CFIR framework was selected because it provides a structured menu of constructs associated with effective implementation. It consists of 5 domains with 39 underlying constructs. As recommended by Damschroder, in this study 8 CFIR constructs based on the relevancy will be measured. During the NGT, participants will be asked questions related to the multi-level implementation factors that will be based on the sample guide available on http://cfirguide.org but tailored for PWID. After posing each question, participants silently generate individual ideas. Then, using a round-robin elicitation process, each person contributes ideas that are recorded visually. They then engage in group discussion to clarify and evaluate the ideas. Items are then grouped by consensus with duplicate items removed. Then, each participant casts three votes on items as they deem them important. Votes are immediately tallied, ranked based on total number of votes, and the facilitator leads a final discussion to review the results. Sessions will take 60 minutes and be audio-recorded and transcribed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04531670
Study type	Interventional
Source	University of Connecticut
Contact
Status	Completed
Phase	N/A
Start date	July 26, 2021
Completion date	February 28, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04157062` - An Open-Label Trial of Repetitive Transcranial Magnetic Stimulation for Opioid Use Disorder	N/A
Enrolling by invitation	`NCT04527926` - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy	N/A
Completed	`NCT04505540` - Start Treatment and Recovery for Opioid Use Disorder	N/A
Completed	`NCT03065049` - Transforming Recovery Through Exercise and Community	N/A
Completed	`NCT04080037` - Assessing Opioid Care Practices Using CPV Patient Simulation Modules	N/A
Recruiting	`NCT05118204` - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization	Phase 4
Suspended	`NCT05001789` - Cognitive Functioning in Opioid Use Disorder	N/A
Active, not recruiting	`NCT04650386` - Examining an Adaptive Approach to Providing Psychosocial Support to Buprenorphine Patients	N/A
Completed	`NCT03715634` - Study of a Novel Subcutaneous Depot Formulation of Buprenorphine	Phase 1
Enrolling by invitation	`NCT04991974` - Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine	Phase 2/Phase 3
Completed	`NCT04122755` - Single Ascending Dose Study of ALA-1000	Phase 1
Recruiting	`NCT04927143` - Encouraging Abstinence Behavior in a Drug Epidemic	Phase 2
Recruiting	`NCT05049460` - Adjunctive Transcranial Stimulation to Reduce Impulsivity in Opiate Use Disorder	N/A
Recruiting	`NCT05028998` - COVID-19-Related Opioid Treatment Policy Evaluation
Completed	`NCT05047627` - Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder	N/A
Active, not recruiting	`NCT04129580` - reSET-O RCT (Randomized Controlled Trial)	N/A
Recruiting	`NCT03923374` - Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
Completed	`NCT04464421` - SMART Effectiveness Trial	N/A
Suspended	`NCT02687360` - Imaging the Effects of rTMS on Chronic Pain	N/A
Completed	`NCT04056182` - Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Testing of the Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs Program — iRaPID

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms